China's pharmaceutical industry has formally entered the Three Kingdoms period - Medical Devices

And Shanghai Industrial Investment (Holdings) Limited ("SIIC") medical establishment of the new plate on the first drug to achieve the merger; China Pharmaceutical Group Corporation (hereinafter referred to as "Sinopharm") following the merger last year, China Biotechnology Corporation ( hereinafter referred to as "in the Health Group") after April 12 this year, the successful restructuring of the Shanghai Institute of Pharmaceutical Industry (hereinafter referred to as "Medical Engineering Institute") set up a new Sinopharm; just 10 days before that, China Resources Group and the Beijing Municipal People Government officially signed the "joint development on the pharmaceutical industry and the microelectronics industry strategy Cooperation Framework Agreement ", CRC formally North pollen sacs into his arms, setting up a new CRC. Thus, with the Big Three domestic pharmaceutical mergers and acquisitions completed in the pharmaceutical industry since 2009, the amount of M & A transactions reached its highest level since 2000, competition in the pharmaceutical market structure changed significantly, the Chinese pharmaceutical industry has formally entered the Three Kingdoms era. New Sinopharm, New Resources, new seating on the drug three scheduled, after re-row seat industry bigwigs surfaced that the state has required the formation of several Chinese leaders at the national group has been initially envisaged.

New Sinopharm Chinese medicine industry is still doing my part of the oldest new Sinopharm. April 12, Biomedical Engineering Institute as a whole into Sinopharm, as its wholly-owned subsidiary enterprises. SASAC perform the function of the enterprises from 127 to 126 adjusted. Biomedical Engineering Institute as a whole into the meaning of the Sinopharm significant. Although the domestic pharmaceutical industry Sinopharm as the absolute leader, but its profits constitute 80% of the representatives from the pharmaceutical company Sinopharm, even if the reorganization of biological products in the Health Group has continued to contribute to high profits, but also always conceal Sinopharm in pharmaceutical industry on the obvious shortcomings. More pressing problem is the first integration of the new drugs coming out positions for east, central enterprise of another giant CRH has never stopped the ambition and the pace of acquisitions, new medical reform in the sinking of the promotion of grass-roots, leading around the region and also not to be outdone , have an alliance against. "Internal and external", the Biomedical Engineering Institute of the Sinopharm has a trump card is a must win.

In Chinese medicine research, Biomedical Engineering Institute has been a proud existence?? As the central rate in the sequence only the pharmaceutical industry and scientific research institutes, medical workers have under the House of Central Enterprise Work Commission, SASAC. Chinese Stock Market section of more than 30 listed companies with its output of scientific research as the main product, target revenue of 1.5 billion yuan in 2010, the main industry is the innovative drug development, pharmaceutical production, sales, R & D leading the country. Although its annual sales income of less than 10 billion, but its strong scientific research strength, as Sinopharm industrial engines and fission devices. Biomedical Engineering Institute of the two subordinate industrial enterprises, the modern pharmaceutical and Shanghai Modern Pharmaceutical Research Center Co., Ltd. are a very good performance, economic and social benefits and even hard to value.

4 22, Shan Xi Weiqi of China Pharmaceutical Group and Yongda (hereinafter referred to as "Weiqi Da"), signed an agreement in Datong, Shanxi, the official start of the Weiqi Da Sinopharm reorganization. Sinopharm committed to increase their investment through equity acquisition and the manner of Weiqi Da achieve Holdings. This is Sinopharm autonomy in the pharmaceutical industry M & A launched a first step, which means great, can accelerate the process of Sinopharm industry, while mergers and acquisitions Weiqi Da, the Sinopharm will certainly open a breach in Shanxi Province, the introduction of other businesses in the region. Weiqi Da is the medical intermediate 7-ACA's major manufacturers, directly downstream of the intermediate product is ceftriaxone. China is a big country to use anti-infective products, the national anti-inflammatory class of drugs at an average annual rate of about 17% of rapid growth, in 2009 the national anti-inflammatory class of drugs has more than 40 billion yuan market scale. Antibiotic ceftriaxone has been ranked first in the amount of drug sales. In 2008, Chinese Pharmaceutical Association had 22 hospitals nationwide statistics, ceftriaxone drugs amounted to 2.6978 billion yuan, far more than other drugs. Shijiazhuang Pharmaceutical Group and Fuzhou Antibiotic Group is a large 7-ACA production, the annual capacity of about 1600 tons. Weiqi Da third place, about 1,000 tons of annual production capacity of enterprises such as health dollars are at 800 tons. In the reorganization agreement, that will further expand Sinopharm Weiqi Da capacity to achieve 1,200 tons 300 tons of 7-ACA and Clavulanic Acid production scale.

Trainer Kits… A Mobile Medicine Miracle Maryland Medical Malpractice: Cancer Misdiagnosis Compare Mexico to others for your next Medical Procedure Laughter Still Is The Best Medicine Micah Group Is The Leader In Remediation A Gay Drug Rehab Element in a very Heterosexual Drug Rehab: The Best Of Each Worlds Low-Cost, High-Value Dermal Filler Training Available Through The Leaders In Medical Training Florida Drug Treatment Centers: Saves Your Life From Drug Addiction Various Approaches to Alcohol and Drug Abuse Rehabilitation How to Choose a Reliable Drug Recovery Center How to get free from the problem of drug addiction Use the Highly Safe Kamagra Drugs to Control ED! Why Choose A Chinese Medicine Candida Remedy?

China's pharmaceutical industry has formally entered the Three Kingdoms period - Medical Devices